Although pTyr397FAK was elevated in all invasive breast cancer cell lines, evidence of increased pTyr397FAK within ALDH+ cells suggest FAK may be a promising target in triple negative breast cancers, where there are no current targeted therapies. This evidence concerns the gene LDHA and triple-negative breast carcinoma.